There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...
Analysts Predict a $102 Target for Viking Therapeutics Inc (VKTX) Stock—What Could Drive It There?
On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...
Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...
With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...
MarketWatch on MSN15d
Viking Therapeutics stock jumps after weight-loss pill shows ‘great outcome’ in trialViking Therapeutics stock soared 21% in early trade Monday after the biotech posted data on its oral weight-loss drug showing ...
Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...
Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...
Viking Therapeutics' shares have soared 200% since January. Its leading candidate for treating obesity helps justify its valuation. The company also has several other medicines in the pipeline.
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech that rose in prominence this year. The drugmaker's shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback